We've found
					52,953 Cancer				
					clinical trials				
				
			
		
							
  	
	Oncology Clinical Trial
	Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endocrinology, Oncology Clinical Trial
	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neoplasms Clinical Trial
	Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being
		Status: Enrolling	
	
	
			Updated: 1/31/2017	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	Open-Label Extension and Safety Study of Talazoparib
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology, Other Clinical Trial
	Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Endometrial Cancer Clinical Trial
	A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
		Status: Enrolling,
							Phase
													 			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Small Cell Lung Cancer Clinical Trial
	Trial of BMS-986012 in Combination With Platinum and Etoposide
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 2/28/2017	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Cancer Clinical Trial
	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Neurology, Oncology Clinical Trial
	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology, Other Clinical Trial
	Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
		Status: Enrolling,
							Phase
													 			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Prostate Cancer Clinical Trial
	Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
		Status: Enrolling,
							Phase
																				 II,  III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Metastatic Breast Cancer Clinical Trial
	An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Metastatic Breast Cancer Clinical Trial
	An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Malignancies Clinical Trial
	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Malignancies Clinical Trial
	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Malignancies Clinical Trial
	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Malignancies Clinical Trial
	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer
		Status: Enrolling	
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Metastatic Pancreatic Cancer Clinical Trial
	A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Metastatic Pancreatic Cancer Clinical Trial
	A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Metastatic Pancreatic Cancer Clinical Trial
	A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
						
				
			
We've found
					52,953 Cancer
				
					clinical trials
				
				
				
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endocrinology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neoplasms Clinical Trial
	
Updated: 1/31/2017
  
  
  Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being
		Status: Enrolling	
	Updated: 1/31/2017
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Open-Label Extension and Safety Study of Talazoparib
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology, Other Clinical Trial
	
Updated: 12/31/1969
  
  
  Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Endometrial Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
		Status: Enrolling,
							Phase
													 			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Small Cell Lung Cancer Clinical Trial
	
Updated: 2/28/2017
  
  
  Trial of BMS-986012 in Combination With Platinum and Etoposide
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 2/28/2017
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Neurology, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology, Other Clinical Trial
	
Updated: 12/31/1969
  
  
  Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
		Status: Enrolling,
							Phase
													 			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Prostate Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
		Status: Enrolling,
							Phase
																				 II,  III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Metastatic Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Metastatic Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Malignancies Clinical Trial
	
Updated: 12/31/1969
  
  
  Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Malignancies Clinical Trial
	
Updated: 12/31/1969
  
  
  Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Malignancies Clinical Trial
	
Updated: 12/31/1969
  
  
  Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Malignancies Clinical Trial
	
Updated: 12/31/1969
  
  
  Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Metastatic Pancreatic Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Metastatic Pancreatic Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Metastatic Pancreatic Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
		Status: Enrolling,
							Phase
																				 I,  II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials